Skip to content
Screener

Vir Biotechnology, Inc. VIR Q4 2025 Annual earnings

Reported February 23, 2026 · After market close

Revenue$64.1MBeat by $44.2M
EPS-$0.31Beat by $0.11
Revenue estimate$19.9M
EPS estimate-$0.42

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$865.1K
EPS estimate-$0.74

Financials

Q4 2025

Income statement

See full
Revenue$64.1M+418%
Operating income-$47.9M+59.1%
Net income-$42.9M+59.0%
EPS (diluted)-$0.30+60.5%

Balance sheet

See full
Cash & equivalents$241.1M-24.4%
Total debt$97.9M0.0%
Total equity$765.3M-33.5%
Total assets$1.0B-28.3%

Cash flow

See full
Operating cash flow-$25.9M+70.5%
CapEx$348.0K-82.6%
Free cash flow-$26.2M+70.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$838.92M-17.0%
Enterprise value$695.71M-11.9%
P/S12.2×-1.4×

Profitability

See full
Operating margin-699.2%-72.9pp
Net margin-638.9%-53.7pp
FCF margin-578.5%-29.5pp

Returns & leverage

See full
Return on equity-45.7%+11.5pp
Debt / equity0.1×0.0×
Current ratio5.5×-3.2×

Segments

By segment

See full
Reportable Segment$64.1M+418%

FAQ

When did Vir Biotechnology, Inc. report Q4 2025 earnings?
Vir Biotechnology, Inc. (VIR) reported Q4 2025 earnings on February 23, 2026 after market close.
What were Vir Biotechnology, Inc.'s Q4 2025 revenue and EPS?
Vir Biotechnology, Inc. reported revenue of $64.1M and eps of $-0.31 for Q4 2025.
Did Vir Biotechnology, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $19.9M by $44.2M. EPS beat the consensus estimate of $-0.42 by $0.11.
How did Vir Biotechnology, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 417.8% from $12.4M a year earlier and eps grew 59.2% from $-0.76.
Where can I find Vir Biotechnology, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-010740) and the 10-K periodic report (0001628280-26-010749) directly on SEC EDGAR. The filing index links above go to sec.gov.